Skip to main content

Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today

HIMS Cover Image

What Happened?

Shares of telehealth company Hims & Hers Health (NYSE: HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, and EBITDA came in a bit short, but revenue soared year over year, easily beating Wall Street's forecasts. This jump came from surging demand in the weight-loss business, which remains a key growth engine. 

That said, EBITDA slightly missed estimates, and gross margin fell from 83% to 77%, signaling rising costs to attract and serve customers. 

Looking ahead, Hims & Hers provided optimistic guidance, projecting full-year 2025 revenue and adjusted EBITDA well above analysts' expectations. 

Overall, we think this was still a solid quarter with some key areas of upside, but the worse-than-anticipated customer additions and EBITDA seem to be sending shares lower. We also note that expectations were high going into the print as the stock was up 104% year-to-date before the announcement.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Hims & Hers Health’s shares are extremely volatile and have had 73 moves greater than 5% over the last year. But moves this big are rare even for Hims & Hers Health and indicate this news significantly impacted the market’s perception of the business. 

The previous big move we wrote about was 4 days ago when the stock dropped 24% on the news that U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as Wegovy and Ozempic has ended. This could lead to lower sales for companies like Hims & Hers Health, which sell weight-loss medications through their platform.

Hims & Hers Health is up 58.2% since the beginning of the year, but at $39.86 per share, it is still trading 42% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $3,947.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.21
+3.12 (1.41%)
AAPL  262.82
+3.24 (1.25%)
AMD  252.92
+17.93 (7.63%)
BAC  52.57
+0.81 (1.56%)
GOOG  260.51
+6.78 (2.67%)
META  738.36
+4.36 (0.59%)
MSFT  523.61
+3.05 (0.59%)
NVDA  186.26
+4.10 (2.25%)
ORCL  283.33
+3.26 (1.16%)
TSLA  433.72
-15.26 (-3.40%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.